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Abstract The role of RasGAP was investigated in the model
system of Xenopus oocytes expressing fibroblast growth factor
receptor 1 (FGFR1) stimulated by fibroblast growth factor 1
(FGF1). The injection of the SH2-SH3-SH2 domains of
RasGAP suppressed Ras activity, extracellular signal-regulated
protein kinase 2 (ERK2) phosphorylation and Mos synthesis.
The SH2 domain of Src, and PP2, an inhibitor of Src, also
abolished Ras activity, ERK2 phosphorylation and Mos syn-
thesis. In addition, Src activity was blocked by the SH2-SH3-
SH2 domains of RasGAP. Immunoprecipitation of a chimera
composed of the extracellular domain of the platelet-derived
growth factor (PDGF) receptor and the intracellular domain of
FGFR1 stimulated by PDGF-BB demonstrates the recruitment
of phosphorylated RasGAP. This study shows that the transduc-
tion cascade induced by the FGFR1^FGF1 interaction in
Xenopus oocytes involves RasGAP as a co-activator of Src to
stimulate the Ras/mitogen-activated protein kinase cascade and
Mos synthesis. It emphasises a new positive regulatory role for
RasGAP in FGFR transduction. ß 2001 Published by Elsevier
Science B.V. on behalf of the Federation of European Biochem-
ical Societies.
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1. Introduction
Fibroblast growth factors (FGFs) exert pleiotropic e¡ects
including cell growth and di¡erentiation. Their responses are
triggered by the activation of four structurally related trans-
membrane tyrosine kinase receptors (FGFRs) [1^3]. Under
ligand stimulation FGFRs transphosphorylate each other
and elicit a pattern of signal transduction dependent on or
independent of Ras [4^6]. Molecular e¡ectors of the Ras-de-
pendent pathway are the adapter proteins Shc, FRS2 and
Grb2 [7,8]. Grb2 is recruited to the membrane in complex
with the Ras-activating nucleotide exchange factor SOS which
in turn activates Ras. Ras is a prototype of a superfamily of
conserved proteins that act as molecular switches and trigger
the activation of mitogen-activated protein kinase (MAPK).
Ras activity is controlled by its bound nucleotide with the
GTP form being the active form competent for cellular signal-
ing. Ras deactivation is ensured by GTPase-activating pro-
teins (GAPs) which greatly speed up GTP hydrolysis [9,10].
RasGAP is a major regulator of cellular Ras activity through
its carboxy-terminal domain that contains the catalytic do-
main which bind Ras-GTP and accelerates GTP hydrolysis.
RasGAP possesses one SH3 domain £anked by two SH2 do-
mains in the amino-terminal region that allows its interaction
with tyrosine kinase receptors and signaling proteins [11,12].
First thought of as merely a downregulator of Ras in tyrosine
kinase receptor transduction, RasGAP turns out to have some
intrinsic e¡ector function and to mediate some of the biolog-
ical e¡ects of Ras [13^17]. Though RasGAP function has
become clearer for many receptor tyrosine kinases (RTKs)
[18^20], its involvement in FGFR transduction is poorly
understood. A report mentioned RasGAP was phosphorylat-
ed and co-immunoprecipitated with FGFR1 in Xenopus blas-
tula. Also RasGAP could behave as a main e¡ector during
Xenopus development [6]. Others reports on cell lines showed
that RasGAP was not associated with FGFR1 and did not
participate in its transduction cascade [21].
To get further insight into the function played by RasGAP
in FGFR1 signaling, we used a model system devoid of
FGFRs, Xenopus oocytes, where FGFRs can be expressed
and stimulated by exogenous FGFs [22^24]. Xenopus oocytes
are physiologically arrested at the G2 stage of the ¢rst meiosis
prophase. They serve as a convenient model system to study
transduction cascades initiated by progesterone [25] and fac-
tors such as insulin-like growth factor (IGF) [26,27] or FGF
[24]. Their binding to appropriate receptors induces the entry
of oocytes into the M phase, which leads to germinal vesicle
breakdown (GVBD), used as an indicator of their meiosis
reinitiation. The transduction cascade involved in meiosis re-
initiation includes a protein kinase A (PKA)-dependent path-
way after progesterone stimulation and a Ras/MAPK-depen-
dent pathway after growth factor addition [27].
In the present study, we analyse the relevance of RasGAP
in the Ras/MAPK transduction cascade and Mos protein syn-
thesis triggered by FGF1 in Xenopus oocytes expressing
FGFR1.
2. Materials and methods
2.1. Oocytes
After anaesthesia with MS 222 (1 g/l, Sandoz), Xenopus laevis ovar-
ian fragments were surgically removed and placed in ND96 medium
(in mM: NaCl 96, KCl 2, MgCl2 1, CaCl2 1.8, HEPES 5, adjusted to
pH 7.4 with NaOH), supplemented with streptomycin/penicillin (50
Wg/ml, Eurobio), sodium pyruvate (225 Wg/ml, Sigma) and soybean
trypsin inhibitor (30 Wg/ml, Sigma) [23,24]. Stage VI oocytes were
harvested by 1 h treatment with collagenase A (1 mg/ml, Boehringer
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Mannheim). Complete defolliculation of the oocytes was achieved by
manual dissection. The oocytes were kept at 19‡C in the ND96 me-
dium.
2.2. cRNA and fusion protein preparation
FGFR1 and a plasmid-derived growth factor receptor (PDGFR)^
FGFR1 chimera inserted into vector pSP64T [28] were used to gen-
erate capped cRNAs (mMESSAGE mMACHINE kit, Ambion). The
SH2-SH3-SH2 domains of RasGAP and the SH2 domain of Src [15]
were expressed in Escherichia coli. The production of glutathione S-
transferase (GST) proteins was induced by addition of 0.1 mM iso-
propyl thio-L-D-galactoside for 3 h. Cells were centrifuged and lysed
by sonication in the following solution: 0.01 M phosphate bu¡er pH
7.5, containing 0.15 M NaCl, 100 mM EDTA, 1% Triton X-100,
1 mM aprotinin, 1 mM phenylmethylsulphonyl £uoride (PMSF).
After addition of 1% Triton X-100 the lysate was centrifuged at
10 000Ug. GST proteins were bound to glutathione-Sepharose 4B
(Pharmacia), washed four times, eluted with 20 mM glutathione and
concentrated using Centricon 3 ¢lters (Amicon).
2.3. Microinjection, drug treatment of oocytes and GVBD analysis
Microinjection were performed with 60 ng of FGFR1 or PDGFR^
FGFR1 cRNAs and 150 ng of SH2-SH3-SH2 of RasGAP or 100 ng
of SH2 of Src in the equatorial region of the oocyte. The SH2-SH3-
SH2 of RasGAP and the SH2 of Src were injected 2 h before addition
of FGF1 (5 nM, RpD system, UK), progesterone (2 Wg/ml) or insulin
(1 WM, Sigma) to the oocytes. PP2, an inhibitor of Src (10 WM)
(Calbiochem), was added to the medium 2 h before FGF1 treatment.
GVBD was determined by the appearance of a white spot at the
centre of the animal pole. Student’s t-test was used to assess the
signi¢cance of the observed di¡erences. For each experiments, 20^30
oocytes were removed from di¡erent animals (n = number of animals).
2.4. Immunoprecipitation of RasGAP
Thirty oocytes expressing PDGFR^FGFR1 for 40 h were stimu-
lated or not with PDGF-BB (5 nM) for 5 min. These oocytes were
lysed in bu¡er A: 50 mM HEPES, pH 7.4, 1% Triton X-100, 500 mM
NaCl, 0.05% SDS, 5 mM MgCl2, 1 mg/ml bovine serum albumin
(BSA), 10 Wg/ml leupeptin, 10 Wg/ml aprotinin, 10 Wg/ml soybean
trypsin inhibitor, 10 Wg/ml benzamidine, 1 mM PMSF, 1 mM sodium
vanadate. After centrifugation, 10 000Ug for 5 min at 4‡C, the super-
natants were incubated with an anti-PDGFR antibody (1/500, Trans-
duction Laboratories) at 4‡C for 2 h. Protein A-agarose (50%, Trans-
duction Laboratories) was added for 1 h at 4‡C. The immune
complexes were collected by centrifugation, rinsed three times, resus-
pended in Laemmli sample bu¡er, and subjected to 7.5% SDS^PAGE.
2.5. Electrophoresis and Western blot analysis
For extracellular signal-regulated protein kinase 2 (ERK2) phos-
phorylation and Mos synthesis analysis, oocytes were homogenised
in ice-cold bu¡er as previously described [29]. Electrophoresis was
performed on 15% modi¢ed polyacrylamide gels (30% acrylamide
and 0.2% bisacrylamide). Proteins were transferred to a Hybond
ECL membrane (Amersham life Sciences) in Tris/NaCl/Tween/BSA
pH 8 (15 mM Tris^HCl, 150 mM NaCl, 0.1% Tween, 10% BSA,
Sigma). The membranes were incubated with anti-ERK2 (1/2500, San-
ta Cruz Biotechnology) for 1 h or with an anti-MosXe (1/500, Upstate
Biotechnology) overnight. For RasGAP analysis, the membranes were
incubated with an anti-RasGAP antibody for 1 h (1/750, Transduc-
tion Laboratories), stripped and reblotted overnight with an anti-
phosphotyrosine antibody (1/1000, Transduction Laboratories). Anti-
body complexes were detected by the enhanced chemoluminescence
Western blotting detection system (Amersham).
2.6. Src assay
Oocytes expressing FGFR1 were lysed 5 min after FGF1 addition
at 4‡C in bu¡er A. The material was harvested, centrifuged at
10 000Ug for 15 min at 4‡C and 200 Wl of oocyte supernatant was
immunoprecipitated with anti-Src (5 Wg/Wl, Santa Cruz) for 1.5 h at
4‡C followed by addition of 40 Wl of protein A-agarose (50%, Trans-
duction Laboratories) agitated for 1.5 h at 4‡C. The immune com-
plexes were collected by centrifugation and rinsed three times with
bu¡er A. Src immunoprecipitates were incubated with 2 Wg of acid-
denatured enolase (Sigma), 20 mM HEPES pH 7.2, 10 mM MnCl2, 20
Wg/ml aprotinin and 20 WCi of [Q-32P]ATP (2 WM) in a total reaction
volume of 20 Wl. The reaction was stopped after 10 min at 30‡C by
adding Laemmli bu¡er. Samples were boiled for 2 min and subjected
to electrophoresis and autoradiography.
2.7. Ras assay
Oocytes expressing FGFR1 for 36 h were incubated at 19‡C in
ND96 with 0.5 mCi/ml [32P]orthophosphate (NEM). They were lysed
in bu¡er A 5 min after FGF1 addition. After centrifugation, immu-
noprecipitation was carried out on supernatants by addition of anti-v-
H-Ras (Y13-259, Calbiochem) coupled to CNBr-activated Sepharose
4B, 3 h under rotation at 4‡C, as previously described [24]. The beads
were washed with bu¡er A. Elution was carried out for 20 min at
65‡C with: 2 mM EDTA, 2 mM dithiothreitol, 0.5 mM GTP, 0.5 mM
GDP. The supernatants were spotted onto a polyethyleneimine cellu-
lose plate and chromatography was carried out with 1 M KH2PO4 at
pH 3.4. GTP and GDP were analysed using a UV lamp and the ratio
of GTP to GDP was determined by quanti¢cation with a phosphoim-
ager. The results are expressed as the percentage of GTP relative to
total GTP plus GDP detected. Each column represents the average þ
S.E.M. from two animals (20 oocytes per animal).
3. Results
3.1. RasGAP is involved in RTK-induced GVBD
The external addition of FGF1 (5 nM) to oocytes express-
ing FGFR1 induced 85.2 þ 14.9% (n = 14) of GVBD which
took place 15^24 h after FGF1 addition. The oocyte meiosis
reinitiation was speci¢c for FGF1R activation since oocytes
expressing FGFR1 unstimulated or treated with genistein (10
WM, an inhibitor of tyrosine kinase activity) or naive oocytes
injected with water 2 h prior to FGF1 stimulation never
underwent GVBD. When oocytes expressing FGFR1 were
treated with SH2-SH3-SH2 of RasGAP (150 ng) 2 h prior
to FGF1 addition, GVBD never occurred (Fig. 1).
Xenopus oocytes express endogenous IGF1R. Insulin treat-
ment (10 WM) of naive oocytes induced GVBD (97.3 þ 4.6%,
n = 3) after the same delay as oocytes expressing FGFR1
stimulated with FGF1. The same inhibition of the GVBD
was detected when SH2-SH3-SH2 of RasGAP (150 ng) were
microinjected 2 h before insulin treatment (Fig. 1).
Addition of progesterone, the natural inducer, in immature
oocytes induced GVBD (83.4 þ 7.4%, n = 3) with a shorter
delay, 8^15 h. In contrast, SH2-SH3-SH2 of RasGAP were
not able to lower the percentage of GVBD (Fig. 1).
Fig. 1. Percentage of GVBD observed after 12^15 h in immature
Xenopus oocytes stimulated with progesterone 2 Wg/ml (PG) or insu-
lin 1 WM (Ins) or in oocytes expressing FGFR1 (60 ng) stimulated
with FGF1 (5 nM). Two hours before stimulation, the oocytes were
injected with SH2-SH3-SH2 of RasGAP (150 ng) (I) or not (C).
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3.2. RasGAP is recruited by the PDGFR^FGFR1 chimera
A chimera composed of the extracellular domain of
PDGFR and the intracellular domain of FGFR1 was ex-
pressed in oocytes. No di¡erences in GVBD percentage were
observed between FGFR1 stimulated with FGF1 (5 nM) and
PDGFR^FGFR1 activated by PDGF-BB (5 nM), as previ-
ously shown [24]. Using an antibody against RasGAP, we
demonstrated that RasGAP is immunoprecipitated with
PDGFR^FGFR1, while it is not in unstimulated controls.
RasGAP was phosphorylated on tyrosine only when oocytes
were stimulated with PDGF-BB (Fig. 2).
3.3. RasGAP is involved in Ras/ERK2 activation and
Mos synthesis
FGF1 stimulation of oocytes expressing FGFR1 (Fig. 3A),
insulin treatment of naive oocytes (Fig. 3B), or progesterone
addition to naive oocytes (Fig. 3C) induced phosphorylation
of ERK2 and synthesis of Mos.
No ERK2 phosphorylation and no Mos synthesis were de-
tected in oocytes expressing FGFR1, and in insulin-treated
oocytes that had received SH2-SH3-SH2 of RasGAP prior
to stimulation with FGF1 (Fig. 3A,B). In contrast, SH2-
SH3-SH2 of RasGAP allowed ERK2 phosphorylation and
Mos synthesis in progesterone-treated oocytes (Fig. 3C).
In addition, Ras activity in oocytes expressing FGFR1
treated with FGF1 was lowered signi¢cantly from 41.4 þ
0.07% to 21.3 þ 0.3% in oocytes treated with SH2-SH3-SH2
of RasGAP (Fig. 4).
3.4. Src kinase is a target for RasGAP in FGFR1 transduction
FGFR1 oocytes stimulated with FGF1 2 h after their treat-
ment with SH2 of Src (100 ng) or PP2 (10 WM), an inhibitor
of Src activity, displayed no GVBD, no ERK2 phosphoryla-
tion and no synthesis of Mos (Fig. 5). As control, GVBD,
ERK2 phosphorylation and Mos synthesis of oocytes treated
with progesterone were not abolished by PP2 addition.
Src activity, present in oocytes expressing FGFR1 stimu-
lated with FGF1, was suppressed by injection of SH2-SH3-
SH2 of RasGAP (Fig. 6).
4. Discussion
In the present study, the role of RasGAP was investigated
in FGFR1 transduction. For this purpose, oocytes expressing
FGFR1 were injected with SH2-SH3-SH2 of RasGAP devoid
of its catalytic domain. This approach uses a competition
which inhibits the association of the endogenous RasGAP
with FGFR1 and other signaling e¡ectors. GVBD was ¢rst
scored to determine the e¡ect of the RasGAP competitor.
Meiosis was reinitiated in oocytes expressing FGFR1 stimu-
lated with FGF1, as previously demonstrated [24], and also in
naive oocytes stimulated with insulin or progesterone. Our
results show that only the transduction pathways triggered
by the two tyrosine kinase receptors were sensitive to the
injection of SH2-SH3-SH2 of RasGAP. It is known that these
receptors transduce messages through a Ras-dependent path-
way, while the progesterone receptor involves a PKA-depen-
Fig. 2. Recruitment of RasGAP by PDGFR^FGFR1. Oocytes ex-
pressing PDGFR^FGFR1 were stimulated (+) or not (3) with
PDGF-BB for 5 min and immunoprecipitated with an anti-PDGFR.
After SDS^PAGE, Western blotting was performed with an anti-
RasGAP followed by an anti-phosphotyrosine antibody.
Fig. 3. Western blot analysis of ERK2 phosphorylation state (-P)
and Mos synthesis. A: Oocytes expressing FGFR1 were stimulated
with FGF1 (5 nM) (C) and injected with SH2-SH3-SH2 of RasGAP
(I). B: Oocytes were stimulated with insulin 1 WM (C) and injected
with SH2-SH3-SH2 of RasGAP (I). C: Oocytes were treated by
progesterone 2 Wg/ml (C) and injected with SH2-SH3-SH2s of Ras-
GAP (I). The injection of SH2-SH3-SH2s of RasGAP (150 ng) was
carried out 2 h before stimulation.
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dent pathway [27]. The lack of e¡ect of SH2-SH3-SH2 of
RasGAP on progesterone-stimulated oocytes is in agreement
with its way of transducing messages in oocytes and attests to
the speci¢c e¡ect of the RasGAP domain used. This further
allowed us to dissect the role of RasGAP in the transduction
cascade triggered by FGFR1^FGF1.
It is known that progesterone and insulin stimulation of
Xenopus oocytes activate the Ras/MAPK cascade and Mos
synthesis [30,31]. We have seen that oocytes expressing
FGFR1, injected with SH2-SH3-SH2 of RasGAP, display a
decrease in Ras activity. Moreover, in these expressing oo-
cytes, ERK2 phosphorylation and Mos synthesis are blocked.
The same e¡ect can be seen for IGFR1-stimulated oocytes,
while progesterone-stimulated oocytes were not sensitive to
this injection. The involvement of RasGAP in the insulin
transduction cascade was previously observed using a modi-
¢ed peptide from the catalytic domain of RasGAP, which
inhibits GAP-stimulated RasGTPase activity. This peptide
blocked insulin- but not progesterone-induced GVBD [32].
Other experiments performed with antibodies raised against
the SH3 domain of RasGAP demonstrate the speci¢c involve-
ment of this domain in GVBD and Mos synthesis, after an
activated form of Ras was injected in oocytes [14]. The fact
that the intracellular part of the PDGF^FGFR1 chimera re-
cruits the tyrosine phosphorylated RasGAP e¡ector supports
its role in FGFR1 transduction. Others have demonstrated
that tyrosine phosphorylation of RasGAP occurred after its
recruitment by activated tyrosine kinase receptors, in associ-
ation with a complex of various SH2-containing proteins
[33,34]. RasGAP is a key element in the Ras signaling path-
way initiated by tyrosine kinase receptors. It has been impli-
cated both as a downregulator and as an e¡ector of Ras
proteins. However, its role in the Ras-mediated signal trans-
duction pathways triggered by FGFR is unclear. Only two
contradictory studies report either an interaction [6] or no
interaction [35] of RasGAP with FGFR1. Our study is there-
fore in favour of a role for RasGAP in FGFR transduction. It
suggests a novel way in which RasGAP positively regulates
signals initiated by FGFR1.
We then determined how RasGAP mediates its e¡ect. Re-
cently, RasGAP was shown to contain binding sites for the
Src family kinase [36]. In the PDGFR transduction pathway
RasGAP interacts with Src to modulate PDGF mitogenic
e¡ect [18]. Furthermore, FGFR1 transduction involves Src
as a mitogenic e¡ector in somatic cells [37] and as a GVBD
inducer in Xenopus oocytes [24]. We have shown that PP2, a
Src inhibitor, and SH2 of Src blocked Ras activity, ERK2
phosphorylation and Mos synthesis, triggered by FGFR1^
FGF1. According to this fact, Src is a main e¡ector in the
FGFR signaling cascade upstream of Ras in oocytes, we
tested the interaction of RasGAP with Src. Using a Src kinase
assay, we demonstrate Src activity is inhibited by SH2-SH3-
SH2 of RasGAP. The di¡erences in the results we obtained
for ERK2 phosphorylation between SH2-SH3-SH2 of Ras-
GAP compared to the injection of SH3 antibodies by others
[14] could be explained by the speci¢c action of RasGAP on
Src activity. E¡ectively, in our study the transduction cascade,
including RasGAP, starts from an RTK upstream of Ras
while the study that uses an anti-SH3 of RasGAP only starts
from activated Ras.
In conclusion, we propose that FGFR1 signaling triggered
by FGF1 addition needs RasGAP as a coactivator of the Src
kinase which activates ERK2 kinase and Mos synthesis. This
suggests a novel role for RasGAP as a positive regulator of
the FGFR1 transduction pathways.
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